PRF Growth Factor ReleasePRFNCT07778160
Comparison of Growth Factor Releases and Degradation Rates of Membranes Obtained From A-PRF+, L-PRF, and Alb-PRF
A study testing Albumin-Platelet Rich Fibrin (Alb-PRF), Advanced Platelet-Rich Fibrin (A-PRF) and Leukocyte-Platelet Rich Fibrin (L-PRF) in people with PRF Growth Factor Release, run by Izmir Katip Celebi University at 1 site in Turkey (Türkiye).
Trial summary
Platelet-rich fibrin (PRF) is widely used in regenerative dentistry because of its autologous growth factor release and fibrin scaffold properties. Different PRF preparations may exhibit different biological characteristics that influence their clinical performance. Read more about this study
- Who is it for?
- Ages 18 to 40 yearsHealthy volunteers can take part
- Conditions the study is for
- PRF Growth Factor Release
- What is being tested?
- Albumin-Platelet Rich Fibrin (Alb-PRF), Advanced Platelet-Rich Fibrin (A-PRF) and Leukocyte-Platelet Rich Fibrin (L-PRF)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Jan 2026to 1 May 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy volunteers aged 18 to 40 years
- Male or female
- Able and willing to provide written informed consent
- Non-smokers
- No history of systemic disease
- No regular medication use
- No use of antibiotics, corticosteroids, or non-steroidal anti-inflammatory drugs within the previous 6 months
Who cannot join
- Age younger than 18 years or older than 40 years
- Smoking
- Pregnancy or breastfeeding
- History of any systemic disease
- Regular medication use
- Use of antibiotics, corticosteroids, or non-steroidal anti-inflammatory drugs within the previous 6 months
- Refusal or inability to provide written informed consent
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Izmir Katip Celebi University Faculty of Dentistry
Izmir, İzmir, 35620
About this study
Platelet-rich fibrin (PRF) is widely used in regenerative dentistry because of its autologous growth factor release and fibrin scaffold properties. Different PRF preparations may exhibit different biological characteristics that influence their clinical performance. This study aims to compare Albumin-PRF (Alb-PRF), Advanced Platelet-Rich Fibrin+ (A-PRF+), and Leukocyte-Platelet Rich Fibrin (L-PRF) regarding cumulative growth factor release and fibrin degradation. Blood samples obtained from healthy volunteers will be processed to prepare all three PRF types. Growth factor release and fibrin degradation will be analyzed under standardized laboratory conditions.
Read the detailed description
Platelet-rich fibrin products have become increasingly popular in regenerative medicine because they provide a fibrin scaffold capable of releasing multiple growth factors over time. However, differences in centrifugation protocols and preparation techniques may significantly affect their biological properties.
Albumin-PRF is a recently introduced modification that combines heat-denatured plasma proteins with injectable PRF to increase scaffold stability and prolong growth factor release.
This study will compare Alb-PRF, A-PRF+, and L-PRF prepared from the same healthy volunteers. Cumulative release of VEGF, PDGF-BB, and TGF-β1 will be evaluated on Days 1, 3, 5, and 7 using ELISA. Resistance to enzymatic degradation will be assessed by measuring delta D-dimer concentrations following trypsin-EDTA exposure. The results are expected to improve understanding of the biological performance of different PRF formulations.
- Conditions
- PRF Growth Factor Release
- Being tested
- Albumin-Platelet Rich Fibrin (Alb-PRF), Advanced Platelet-Rich Fibrin (A-PRF), Leukocyte-Platelet Rich Fibrin (L-PRF)
- Keywords
- Alb-PRF, L-PRF, growth factor, e-PRF, degredation, PRF membrane, A-PRF+
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Albumin-Platelet Rich Fibrin (Alb-PRF)Biological
Autologous Albumin-Platelet Rich Fibrin prepared from peripheral venous blood using the Alb-PRF protocol for evaluation of growth factor release and enzymatic degradation.
Advanced Platelet-Rich Fibrin (A-PRF)Biological
Autologous Advanced Platelet-Rich Fibrin+ prepared from peripheral venous blood using the A-PRF+ protocol for evaluation of growth factor release and enzymatic degradation.
Leukocyte-Platelet Rich Fibrin (L-PRF)Biological
Autologous Leukocyte-Platelet Rich Fibrin prepared from peripheral venous blood using the L-PRF protocol for evaluation of growth factor release and enzymatic degradation.
| Study group | Role | What they receive |
|---|---|---|
| Albumin-Platelet Rich Fibrin (Alb-PRF) | Experimental | Blood samples obtained from healthy volunteers were processed using the Albumin-Platelet Rich Fibrin (Alb-PRF) protocol. Growth factor release and resistance to enzymatic degradation were evaluated under standardized laboratory conditions. Receives: Biological: Albumin-Platelet Rich Fibrin (Alb-PRF) |
| Leukocyte-Platelet Rich Fibrin (L-PRF) | Experimental | Blood samples obtained from healthy volunteers were processed using the Leukocyte-Platelet Rich Fibrin (L-PRF) protocol. Growth factor release (VEGF, PDGF-BB, and TGF-β1) and resistance to enzymatic degradation were evaluated under standardized laboratory conditions and compared with Albumin-PRF (Alb-PRF) and Advanced Platelet-Rich Fibrin+ (A-PRF+). Receives: Biological: Leukocyte-Platelet Rich Fibrin (L-PRF) |
| Advanced - Platelet Rich Fibrin+ (A-PRF+) | Experimental | Blood samples obtained from healthy volunteers were processed using the Advanced Platelet-Rich Fibrin+ (A-PRF+) protocol. Growth factor release (VEGF, PDGF-BB, and TGF-β1) and resistance to enzymatic degradation were evaluated under standardized laboratory conditions and compared with Albumin-PRF (Alb-PRF) and Leukocyte-Platelet Rich Fibrin (L-PRF) . Receives: Biological: Advanced Platelet-Rich Fibrin (A-PRF) |
What is being measured
The primary outcome is the main question the study is designed to answer.
VEGF concentration released from PRF membranes
Quantitative assessment of VEGF released from Albumin-PRF (Alb-PRF), Advanced Platelet-Rich Fibrin+ (A-PRF+), and Leukocyte-Platelet Rich Fibrin (L-PRF) using enzyme-linked immunosorbent assay (ELISA).
Measured: Day 1, Day 3, Day 5, and Day 7
PDGF concentration released from PRF membranes
Quantitative assessment of PDGF released from Albumin-PRF (Alb-PRF), Advanced Platelet-Rich Fibrin+ (A-PRF+), and Leukocyte-Platelet Rich Fibrin (L-PRF) using enzyme-linked immunosorbent assay (ELISA).
Measured: Day 1, Day 3, Day 5, and Day 7
TGF-B concentration released from PRF membranes
Quantitative assessment of TGF-B released from Albumin-PRF (Alb-PRF), Advanced Platelet-Rich Fibrin+ (A-PRF+), and Leukocyte-Platelet Rich Fibrin (L-PRF) using enzyme-linked immunosorbent assay (ELISA).
Measured: Day 1, Day 3, Day 5, and Day 7
Resistance to enzymatic degradation
Assessment of fibrin degradation by measuring D-dimer levels after enzymatic digestion of PRF preparations.
Measured: 60 minutes and 120 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Aug 2026
- Study start1 Jan 2026
- Primary completion1 Mar 2026
- Study completion1 May 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PRF Growth Factor ReleaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Crossover
- Model description
- Blood samples obtained from each healthy volunteer were used to prepare Albumin-PRF (Alb-PRF), Advanced Platelet-Rich Fibrin+ (A-PRF+), and Leukocyte-Platelet Rich Fibrin (L-PRF). Growth factor release and fibrin degradation characteristics of the three PRF preparations were compared under standardized laboratory conditions.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 10 participants (actual)
Sponsor and investigators
- Lead sponsor
- Izmir Katip Celebi University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hülya Anak, Izmir Katip Celebi University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07778160
- Sponsor's protocol ID
- 2025-TDU-DİŞF-0014
- Acronym
- PRF
- Status last verified
- Aug 2026
- First submitted
- 29 Jul 2026
- Last updated
- 21 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of Growth Factor Releases and Degradation Rates of Membranes Obtained From A-PRF+, L-PRF, and Alb-PRF
- ClinicalTrials.gov ID
- NCT07778160
- Acronym / sponsor ID
- PRF / 2025-TDU-DİŞF-0014
- Conditions
- PRF Growth Factor Release
- Keywords
- Alb-PRF, L-PRF, growth factor, e-PRF, degredation, PRF membrane, A-PRF+
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 10 participants (actual)
- Lead sponsor
- Izmir Katip Celebi UniversityUniversity, hospital or other
- Study start
- 1 Jan 2026 (actual)
- Primary completion
- 1 Mar 2026 (actual)
- Study completion
- 1 May 2026 (actual)
- First posted
- 21 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Platelet-rich fibrin (PRF) is widely used in regenerative dentistry because of its autologous growth factor release and fibrin scaffold properties. Different PRF preparations may exhibit different biological characteristics that influence their clinical performance. This study aims to compare Albumin-PRF (Alb-PRF), Advanced Platelet-Rich Fibrin+ (A-PRF+), and Leukocyte-Platelet Rich Fibrin (L-PRF) regarding cumulative growth factor release and fibrin degradation. Blood samples obtained from healthy volunteers will be processed to prepare all three PRF types. Growth factor release and fibrin degradation will be analyzed under standardized laboratory conditions.
Detailed description
Platelet-rich fibrin products have become increasingly popular in regenerative medicine because they provide a fibrin scaffold capable of releasing multiple growth factors over time. However, differences in centrifugation protocols and preparation techniques may significantly affect their biological properties.
Albumin-PRF is a recently introduced modification that combines heat-denatured plasma proteins with injectable PRF to increase scaffold stability and prolong growth factor release.
This study will compare Alb-PRF, A-PRF+, and L-PRF prepared from the same healthy volunteers. Cumulative release of VEGF, PDGF-BB, and TGF-β1 will be evaluated on Days 1, 3, 5, and 7 using ELISA. Resistance to enzymatic degradation will be assessed by measuring delta D-dimer concentrations following trypsin-EDTA exposure. The results are expected to improve understanding of the biological performance of different PRF formulations.
Study design
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Crossover
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 3
- Model description
- Blood samples obtained from each healthy volunteer were used to prepare Albumin-PRF (Alb-PRF), Advanced Platelet-Rich Fibrin+ (A-PRF+), and Leukocyte-Platelet Rich Fibrin (L-PRF). Growth factor release and fibrin degradation characteristics of the three PRF preparations were compared under standardized laboratory conditions.
| Arm | Type | Receives |
|---|---|---|
| Albumin-Platelet Rich Fibrin (Alb-PRF) | Experimental | Biological: Albumin-Platelet Rich Fibrin (Alb-PRF)Blood samples obtained from healthy volunteers were processed using the Albumin-Platelet Rich Fibrin (Alb-PRF) protocol. Growth factor release and resistance to enzymatic degradation were evaluated under standardized laboratory conditions. |
| Leukocyte-Platelet Rich Fibrin (L-PRF) | Experimental | Biological: Leukocyte-Platelet Rich Fibrin (L-PRF)Blood samples obtained from healthy volunteers were processed using the Leukocyte-Platelet Rich Fibrin (L-PRF) protocol. Growth factor release (VEGF, PDGF-BB, and TGF-β1) and resistance to enzymatic degradation were evaluated under standardized laboratory conditions and compared with Albumin-PRF (Alb-PRF) and Advanced Platelet-Rich Fibrin+ (A-PRF+). |
| Advanced - Platelet Rich Fibrin+ (A-PRF+) | Experimental | Biological: Advanced Platelet-Rich Fibrin (A-PRF)Blood samples obtained from healthy volunteers were processed using the Advanced Platelet-Rich Fibrin+ (A-PRF+) protocol. Growth factor release (VEGF, PDGF-BB, and TGF-β1) and resistance to enzymatic degradation were evaluated under standardized laboratory conditions and compared with Albumin-PRF (Alb-PRF) and Leukocyte-Platelet Rich Fibrin (L-PRF) . |
Who may qualify
- Ages
- 18 to 40 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (7 listed)
- Healthy volunteers aged 18 to 40 years
- Male or female
- Able and willing to provide written informed consent
- Non-smokers
- No history of systemic disease
Key exclusion criteria (7 listed)
- Age younger than 18 years or older than 40 years
- Smoking
- Pregnancy or breastfeeding
- History of any systemic disease
- Regular medication use
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Albumin-Platelet Rich Fibrin (Alb-PRF)Autologous Albumin-Platelet Rich Fibrin prepared from peripheral venous blood using the Alb-PRF protocol for evaluation of growth factor release and enzymatic degradation. | Biological | Albumin-Platelet Rich Fibrin (Alb-PRF) |
| Advanced Platelet-Rich Fibrin (A-PRF)Autologous Advanced Platelet-Rich Fibrin+ prepared from peripheral venous blood using the A-PRF+ protocol for evaluation of growth factor release and enzymatic degradation. | Biological | Advanced - Platelet Rich Fibrin+ (A-PRF+) |
| Leukocyte-Platelet Rich Fibrin (L-PRF)Autologous Leukocyte-Platelet Rich Fibrin prepared from peripheral venous blood using the L-PRF protocol for evaluation of growth factor release and enzymatic degradation. | Biological | Leukocyte-Platelet Rich Fibrin (L-PRF) |
Primary outcome
VEGF concentration released from PRF membranes
Time frame: Day 1, Day 3, Day 5, and Day 7
Quantitative assessment of VEGF released from Albumin-PRF (Alb-PRF), Advanced Platelet-Rich Fibrin+ (A-PRF+), and Leukocyte-Platelet Rich Fibrin (L-PRF) using enzyme-linked immunosorbent assay (ELISA).
PDGF concentration released from PRF membranes
Time frame: Day 1, Day 3, Day 5, and Day 7
Quantitative assessment of PDGF released from Albumin-PRF (Alb-PRF), Advanced Platelet-Rich Fibrin+ (A-PRF+), and Leukocyte-Platelet Rich Fibrin (L-PRF) using enzyme-linked immunosorbent assay (ELISA).
TGF-B concentration released from PRF membranes
Time frame: Day 1, Day 3, Day 5, and Day 7
Quantitative assessment of TGF-B released from Albumin-PRF (Alb-PRF), Advanced Platelet-Rich Fibrin+ (A-PRF+), and Leukocyte-Platelet Rich Fibrin (L-PRF) using enzyme-linked immunosorbent assay (ELISA).
Resistance to enzymatic degradation
Time frame: 60 minutes and 120 minutes
Assessment of fibrin degradation by measuring D-dimer levels after enzymatic digestion of PRF preparations.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for PRF Growth Factor Release
Active, not recruitingObservational study
Release Kinetics in PRF Versus GEM21S With and Without Bone Substitutes: An In Vitro Analysis
Bone Loss
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Albumin-Platelet Rich Fibrin (Alb-PRF), Advanced Platelet-Rich Fibrin (A-PRF) and Leukocyte-Platelet Rich Fibrin (L-PRF) in people with PRF Growth Factor Release, run by Izmir Katip Celebi University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
VEGF concentration released from PRF membranes (time frame: Day 1, Day 3, Day 5, and Day 7). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Aug 2026.